Newleos Therapeutics
Brian Shea currently serves as Vice President and Head of Legal at Newleos Therapeutics since April 2025. Prior to this role, Brian held the position of Vice President, Legal at uniQure from November 2023 to April 2025, where oversight of the corporate-legal function was a key responsibility. Brian's career includes leadership positions such as President and Interim Chief Executive Officer at Oncorus, alongside serving as General Counsel, focusing on RNA-based therapeutics for cancer. Previous legal roles include positions at Ropes & Gray LLP, Mintz, and Financial Recovery Technologies, among others, specializing in securities, corporate governance, and strategic transactions. Brian holds a Doctor of Law (J.D.), Cum Laude, from William & Mary Law School and a Bachelor of Arts in Government from Dartmouth College.
This person is not in any teams
This person is not in any offices
Newleos Therapeutics
We are dedicated to providing a new dawn or "eos" for patients with mental health conditions by developing next generation, first- and best-in-class therapies. Over 100 million patients in the United States are affected by neuropsychiatric disorders, with anxiety and substance use disorders among the largest areas of unmet medical need. Our clinical-stage pipeline was licensed from Roche and includes oral small molecules targeting GABAA-γ1, V1a, TAAR1 and GABAA-α5 with broad potential in general anxiety, social anxiety, substance use disorders and cognitive impairment. Newleos was co-founded by Longwood Fund, Federico Bolognani, M.D., Ph.D., and William Martin, Ph.D., seasoned experts in company creation and CNS drug development.